Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy : A Systematic Review Jasmine Turna, Sabrina K. Syan, Benicio N. Frey, Brian Rush, Mary Jean Costello, Mark Weiss, and James MacKillop ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 1-14 Abstract : There is substantial interest in the therapeutic potential of cannabidiol (CBD), a nonpsychoactive cannabinoid found in plants of the genus Cannabis. The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a candidate pharmacotherapy for alcohol use disorder (AUD). Using a comprehensive search strategy, 303 unique potential articles were identified [...]
Lire la suiteChanges in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands Tom P. Freeman, Peggy van der Pol, Wil Kuijpers, Jeroen Wisselink, Ravi K. Das, Sander Rigter, Margriet van Laar, Paul Griffiths, Wendy Swift, Raymond Niesink and Michael T. Lynskey Psychological Medicine, 2018 https://doi.org/10.1017/S0033291717003877 Abstract Background : The number of people entering specialist drug treatment for cannabis problems has increased considerably in recent years. The reasons for this are unclear, but rising cannabis potency could be a contributing factor. Methods : Cannabis potency data were obtained from an ongoing monitoring programme in the Netherlands. We analysed concentrations of δ-9-tetrahydrocannabinol (THC) from [...]
Lire la suiteS224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NONUSERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE Marco Colizzi, Philip McGuire, Vincent Giampietro, Steve Williams1, Mick Brammer, Sagnik Bhattacharyya Schizophrenia Bulletin, Poster, Session III, April 2018 Background : Cannabis use can induce acute and long-lasting psychosis and cognitive dysfunction. Some evidence suggests that the acute behavioral and neurocognitive effects of the main active ingredient in cannabis, (−)-trans-Δ9-tetrahydrocannabinol (Δ9-THC), might be modulated by previous cannabis exposure. However, this has not been investigated either using a control group of non-users, or following abstinence in modest cannabis users, who represent the majority [...]
Lire la suiteDelta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis Marco Colizzi, Nathalie Weltens, Philip McGuire, David Lythgoe, Steve Williams, Lukas Van Oudenhove, Sagnik Bhattacharyya Molecular Psychiatry, 15 February 2019 https://doi.org/10.1038/s41380-019-0374-8 Abstract : The neurobiological mechanisms underlying the association between cannabis use and acute or long lasting psychosis are not completely understood. While some evidence suggests altered striatal dopamine may underlie the association, direct evidence that cannabis use affects either acute or chronic striatal dopamine is inconclusive. In contrast, pre-clinical research suggests that cannabis may affect dopamine via modulation of glutamate signaling. A double-blind, randomized, placebo-controlled, crossover design was used to investigate whether altered [...]
Lire la suiteCOMMENTARY What's the Standard of Care for Managing Medical Marijuana? Carolyn Buppert, MSN, JD Medscape, April 22, 2019 https://www.medscape.com/viewarticle/911912 A Patient on Medical Marijuana A primary care provider in a state where medical marijuana is legal asked the following question: In my state, an individual can get a recommendation for medical marijuana from a qualified practitioner who has a visit with that person for that reason only. Alternatively, the individual's primary care provider or specialist can recommend it. I have recommended medical marijuana for several of my patients who had conditions qualifying them for medical marijuana. My concern is about my patients who have been qualified for [...]
Lire la suiteWEEDS - A propos du documentaire de Fab Five Freddy diffusé sur Netflix : Grass is greener DOPAMINE, 2019, 04, A l'heure où les Etats-Unis font voler en éclat le régime prohibitionniste concernant le cannabis, un retour en arrière dans le temps est nécessaire pour comprendre quelles ont été les motivations des gouvernements successifs pour mettre au banc des accusés une plante verte et des consommateurs qui, s'ils se faisaient du bien ou du mal, ne le faisaient qu'à eux-mêmes sans déranger qui que ce soit... Bien entendu, ne comptez pas sur ce documentaire, réalisé et conté par Fab Five Freddy, ancien [...]
Lire la suite8e Conférence Internationale sur les Avancées Pharmacologiques et Utilisations thérapeutiques des Cannabinoïdes Vendredi 28 juin 2019 à 08:30 https://ufcm-i-care.assoconnect.com/billetterie/offre/104836-v-8e-conference-internationale-sur-les-avancees-pharmacologiques-et-utilisations-therapeutiques-des-cannabinoides Toute l'équipe de l'UFCM-I-Care est ravie de vous accueillir pour son 8e colloque international sur les avancées pharmacologiques et utilisations thérapeutiques des cannabinoïdes en médecine. Il se tiendra à la Faculté de Pharmacie de Strasbourg et sera ouvert par Bertrand Rambaud et Christian Muller, respectivement, les responsables du Pôle Patient et responsable du Pôle Scientifique de l’UFCM-I-Care. L’évènement se tiendra le 28 juin 2019 et se déroulera sur toute la journée, de 8h30 à 18h30. L'inscription est de 20€ pour les professionnels de la santé et les professionnels du [...]
Lire la suiteDOPAMINE - Culture, Drogues et Société, #04 - Avril 2019 DOPAMINE est une revue numérique mensuelle, tout public, dont les articles sont disponibles en continu sur le site. La plupart sont réservés aux abonnés qui reçoivent tous les mois la revue au format PDF. Cette parution s’adresse à tous ceux qui veulent satisfaire leur curiosité et approfondir leurs connaissances, leur regard et réflexion sur la thématique des drogues et addictions, et leurs représentations. DOPAMINE présente, chronique et décrypte un ensemble de références piochées dans l'actualité culturelle : essais, romans, récits de vie, films, séries, vidéos, revues, enquêtes, rapport ou autres documents... [...]
Lire la suiteDescriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans Marco Colizzi, NathalieWeltens, Philip McGuire, Lukas Van Oudenhove and Sagnik Bhattacharyya Brain Sciences, 2019, 9, 93 doi:10.3390/brainsci9040093 Abstract : Background : Cannabis use can increase the risk of psychosis, and the acute administration of its key psychoactive ingredient, delta-9-tetrahydrocannabinol (D9-THC), can induce transient psychotomimetic symptoms. Methods: A double-blind, randomized, placebo-controlled crossover design was used to investigate the symptomatic eects of acute intravenous administration of D9-THC (1.19 mg/2 mL) in 16 healthy participants (seven males) with modest previous cannabis exposure. Results : In the 20 min following acute D9-THC administration, symptomatic eects of at [...]
Lire la suiteThe effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers C. Hindocha, T. P. Freeman, M. Grabski, H. Crudgington, A. C. Davies, J. B. Stroud, R. K. Das, W. Lawn, C. J. A. Morgan & H. V. Curran Scientific Reports, 2018, 8, 7568 DOI:10.1038/s41598-018-25846-2 Abstract : Acute nicotine abstinence in cigarette smokers results in deficits in performance on specific cognitive processes, including working memory and impulsivity which are important in relapse. Cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, has shown pro-cognitive effects and preliminary evidence has indicated it can reduce the number of cigarettes smoked in dependent smokers. However, the effects [...]
Lire la suite